Thursday, July 10, 2014





FDA approves 4-in-1 HIV combination pill


February 16. 2013 7:59PM
Story Tools
PrintPrint | E-MailEMail | SaveSave | Hear Generate QR Code QR
Send to Kindle


(AP) The Food and Drug Administration says it has approved a new anti-HIV pill that combines four medicines to combat the virus in patients who have not previously been treated for infection.


The agency approved Gilead Sciences' Stribild as a once-a-day treatment to control the virus that causes AIDS.


The pill contains two previously approved antiviral drugs currently sold as the combination pill Truvada. Those drugs are combined with two new drugs, elvitegravir and cobicistat. Elvitegravir interferes with one of the enzymes that HIV needs to multiply. Cobicistat helps prolong the effect of elvitegravir.


Company studies showed that 88 to 90 percent of patients taking Stribild had an undetectable level of HIV in their blood after 48 weeks, compared with 84 and 87 percent for patients taking older HIV drugs.


Associated Press


Comments
comments powered by Disqus Commenting Guidelines
Poll
Mortgage Minute


Search for New & Used Cars

Make 
Model
 
Used New All
 

Search Times Leader Classifieds to find just the home you want!

Search Times Leader Classifieds to find just what you need!

Search Pet Classifieds
Dogs Cats Other Animals



Social Media/RSS
Times Leader on Twitter
Times Leader on Youtube
Times Leader on Google+
The Times Leader on Tumblr
The Times Leader on Pinterest
Times Leader RSS Feeds